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OBJECTIVE—Nephrin, an immunoglobulin-like protein essen-
tial for the function of the glomerular podocyte and regulated in
diabetic nephropathy, is also expressed in pancreatic -cells,
where its function remains unknown. The aim of this study was
to investigate whether diabetes modulates nephrin expression in
human pancreatic islets and to explore the role of nephrin in
-cell function.
RESEARCH DESIGN AND METHODS—Nephrin expression
in human pancreas and in MIN6 insulinoma cells was studied by
Western blot, PCR, confocal microscopy, subcellular fraction-
ation, and immunogold labeling. Islets from diabetic (n  5) and
nondiabetic (n  7) patients were compared. Stable transfection
and siRNA knockdown in MIN-6 cells/human islets were used to
study nephrin function in vitro and in vivo after transplantation
in diabetic immunodeﬁcient mice. Live imaging of green ﬂuores-
cent protein (GFP)-nephrin–transfected cells was used to study
nephrin endocytosis.
RESULTS—Nephrin was found at the plasma membrane and on
insulin vesicles. Nephrin expression was decreased in islets from
diabetic patients when compared with nondiabetic control sub-
jects. Nephrin transfection in MIN-6 cells/pseudoislets resulted in
higher glucose-stimulated insulin release in vitro and in vivo after
transplantation into immunodeﬁcient diabetic mice. Nephrin
gene silencing abolished stimulated insulin release. Confocal
imaging of GFP-nephrin–transfected cells revealed nephrin en-
docytosis upon glucose stimulation. Actin stabilization prevented
nephrin trafﬁcking as well as nephrin-positive effect on insulin
release.
CONCLUSIONS—Our data suggest that nephrin is an active
component of insulin vesicle machinery that may affect vesicle-
actin interaction and mobilization to the plasma membrane.
Development of drugs targeting nephrin may represent a novel
approach to treat diabetes. Diabetes 59:190–199, 2010
I
n the U.S. alone, diabetes affects 20 million people.
Although advances have been made in the clinical
care of diabetes, one of the major limitations for
ﬁnding a cure is that the mechanisms regulating the
function of insulin-producing cells have not yet been fully
characterized.
Nephrin is an immunoglobulin-like protein with impor-
tant structural and signaling properties (1,2). It was ini-
tially described in podocytes, highly specialized cells in
the kidney glomerulus (3,4). Nephrin is heavily downregu-
lated in human diabetic nephropathy (5), and nephrin
mutations are responsible for the congenital nephrotic
syndrome of the Finnish type (6).
Nephrin expression has been reported in pancreatic
-cells (7), where its function remains unknown. In immor-
talized human podocytes, the COOH-terminal portion of
nephrin appears to bind VAMP-2, a vesicle-associated mem-
brane protein involved in exocytosis (8). The interaction of
nephrin with VAMP-2, together with its well-known interac-
tion with the actin cytoskeleton (9–13), suggests that nephrin
may play an important role in vesicles trafﬁcking, a recently
described feature of podocyte biology (14).
In pancreatic -cells, glucose stimulation affects actin
reorganization, and redistribution of cortical actin is es-
sential for proper -cell function (15). However, the path-
ways responsible for the regulated targeting of vesicles to
the plasma membrane have not yet been fully character-
ized. The aim of this study was to understand the regula-
tion of pancreatic nephrin expression in patients with type
2 diabetes and the role of nephrin in the regulation of
glucose-stimulated insulin release (GSIR).
RESEARCH DESIGN AND METHODS
Cell culture, islet culture, and RT-PCR. MIN6 cells, and the B1 and C3
subclones (a gift from Dr. A. Thomas), were cultured in 25 mmol/l glucose DMEM
(Invitrogen, Carlsbad, CA) (16), and pseudoislets were generated in culture on a
shaker incubator (17). To study the effect of acute versus chronic glucose
exposure, cells were cultured in 2 mmol/l glucose for 7 days and then assigned to
receive either 2 or 20 mmol/l glucose culture media for 1 day (acute exposure) or
14 days (chronic exposure), a model we have used previously to mimic gluco-
toxicity in mesangial cells (18). Media supplemented with 5 mmol/l leucine and
glutamine were used throughout the experiment to prevent apoptosis related to
prolonged low glucose exposure (19), and cells were subcultured as necessary to
prevent overconﬂuence. For selected experiments, cells were treated for 6 h with
0–200 nmol/l cytochalasin D (Sigma) (20), 0.5 mol/l jasplakinolide (21), or 200
nmol/l phalloidin (Invitrogen), and the change in G/F actin ratio was assessed by
Western blot (G-actin/F-actin Assay Kit; Cytoskeleton, Denver, CO). Human islets
from cadaveric donors with research consent were obtained through the Islet Cell
Resource Distribution system or were isolated at the local Human Cell Processing
facility (22). -cell content was determined as previously described by laser
scanning cytometry (23). Nephrin and 18S rRNA expression were evaluated using
the 7500 Real-Time-PCR System (Applied Biosystems). For standard PCR and
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190 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgsequencing, primers were designed at the intron-exon junction (5-ATCTCCAA
GACCCCAGGTACACA and 3-AGGGTCAGGACGGCTGAT for mouse, 5-CCT
GCTAGAGGTGAATTCCA and 3-CCATTCTTCAGCCACTGCA for human).
Additional human primers previously described were used to verify the presence
of the two described splice variants of nephrin (24). Actin was used as the
housekeeping gene (5-TCATGAGGTAGTCCGTCAGG and 3-TCTAGGCAC
CAAGGTGTG). A PCR product of 938 bp including part of the extracellular
nephrin domain was ampliﬁed and sequenced from human pancreas, and the
blast analysis matched completely the reported human nephrin mRNA sequence.
Western blotting and cell fractionation. For Western blotting, a polyclonal
guinea pig anti-nephrin antibody (1:2,000, COOH-terminal; Fitzgerald Labora-
tories, Concord, MA) and a monoclonal antibody against the IgG8-like domain
of human nephrin (1:500; 50A9, a gift of Dr. Tryggvason) were used. Both
antibodies revealed a unique band of 180 kDa. Loading efﬁciency was veriﬁed
by actin (1:5,000; Abcam, Cambridge, MA). Plasma membranes were sepa-
rated after biotinylation of cultured cells (Thermo Scientiﬁc, Rockford, IL).
Unbiotinylated cells were used as control, and separation efﬁciency was
evaluated by Western blotting for Na/K-ATPase (1:1,000, rabbit polyclonal,
Abcam). For sucrose gradient centrifugation, cells were glucose-starved for
1 h and then exposed to either 0.5 or 25 mmol/l glucose for 30 min and then
homogenized in 250 l HEPES buffer. Pooled supernatants were loaded onto
a 4.4-ml linear sucrose density gradient, centrifuged in a SW50 rotor (110,000g)
for 18 h, and 15–16 fractions were collected from the top of the gradient. A
total of 20 g protein from each fraction was analyzed by immunoblotting;
E-Cadherin was used as a plasma membrane marker (1:1,000, mouse mono-
clonal; BD Bioscience, San Jose, CA); VAMP-2 (1:1,000, rabbit polyclonal;
Assay Designs, Ann Arbor, MI) and insulin (1:3,000, chicken polyclonal;
Abcam) were used for vesicles fractions.
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FIG. 1. Modulation of nephrin expression by diabetes and glucose. A: Characteristics of pancreas donors with or without type 2 diabetes. BMI was
signiﬁcantly different among groups. B: Correlation between the nephrin mRNA expression relative quantiﬁcation (RQ) in isolated islets and BMI among the
12 patients studied. An r
2of 0.75 with P<0.001 revealed that higher BMIs were associated with lower nephrin expression. Circled in red are the ﬁve diabetic
donors. n  2 denotes overlapping points. C: A representative immunoﬂuorescence confocal image for nephrin, insulin, and DAPI in human islets from a
diabetic and nondiabetic donor is shown (20magniﬁcation). A white scale bar of 50 m is provided. D–E: Quantitative analysis of nephrin mRNA expression
in human islets (D) or MIN6 cells (E,f) cultured at either 2 or 20 mmol/l glucose for 24 h. Chronic exposure to high glucose concentration was tested in MIN6
cells only. Cells “starved” in 2 mmol/l glucose for 7 days were assigned to either 2 or 20 mmol/l glucose culture for an additional 14 days. A downregulation
of nephrin mRNA expression was observed (E, ). Mean and SD of four independent experiments are shown. *P < 0.05. (A high-quality color digital
representation of this ﬁgure is available in the online issue.)
A. FORNONI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 191Cell transfection and siRNA. A full-length human nephrin-pCDNA3 vector
was used to generate stable transfected MIN6 cells (Fugene-6; Millipore,
Millerica, MA). The empty pCDNA3 vector was used as a negative control
(CTRL). Four separate clones were used to repeat experiments. An enriched
population of MIN6 cells transfected with a green ﬂuorescent protein (GFP)-
nephrin construct was also obtained with a combination of antibiotic selec-
tion and ﬂuorescence-activated cell sorting (FACS; Aria cells sorter with Diva
6.0 software). For nephrin siRNA in MIN6 cells, a pool of four siRNAs was
transfected (On Target Plus SMART pool; Dharmachon, Lafayette, CO).
siRNAs were tested separately for their efﬁciency to downregulate nephrin
without affecting four other randomly chosen genes. Nephrin expression after
siRNA was veriﬁed by PCR and Western blotting. A pool of nontargeting
siRNA was used as control. To perform gene silencing in human islets, islet
cells were dissociated by incubation at 37°C for 5 min in Accutase (Innovative
Cell Technologies, San Diego, CA). The 0.4  10
6 single cells in each well of
a six-well plate were cultured overnight in CMRL-1066 (Invitrogen) and then
transfected with 3.5 g of a pool of four nontargeting siRNA and human
nephrin siRNA (Dharmacon) using 6 l of DharmaFECT1 in 2 ml ﬁnal volume.
After 3.5 days, 0.2  10
6 single islet cells were used for PCR and perifusion
experiments.
Confocal microscopy, electron microscopy, and immunogold labeling. The
50A9 anti-nephrin antibody was used for immunohistochemistry (Histostain-Plus;
Zymed Laboratories, San Francisco, CA). For colocalization studies, immunoﬂu-
orescence on frozen sections was performed with tyramide signal ampliﬁcation
(TSA kit; Invitrogen). Alexa-647–conjugated antibodies were used as secondary
antibodies for other targets (1:200; Invitrogen). An irrelevant IgG2b antibody
(R&D System, Minneapolis, MN) was used as the negative control. Antibodies for
insulin (1:1,000; Mouse monoclonal, NeoMarkers), glucagon (rabbit polyclonal
1:500; Sigma), somatostatin (rabbit polyclonal 1:500; Sigma), CD31 (goat poly-
clonal; Abcam), and VAMP2 (1:500, mouse monoclonal; Synaptic System,
Goettingen, Germany) were used. For immunocytochemistry, GFP-neph-
rin–transfected cells were ﬁxed with 4% paraformaldehyde and counter-
stained with rhodhamine-phalloidin and 4,6-diamidino-2-phenylindole
dihydrochloride (DAPI) (Invitrogen). When the same cells were used to study
plasma membrane internalization upon glucose stimulation, cells were incu-
bated with 2 or 20 mmol/l glucose medium for 20 min at 37°C, followed by a
pulse incubation for 30 min with 5 mol/l FM1–43 (Invitrogen) (25). Image
acquisition was performed with a Leica SP5-confocal-DMI6000 microscope.
For the quantiﬁcation of vesicles number, cells were ﬁxed in 2% glutaralde-
hyde/100 mmol/l sucrose/0.05 mol/l PO4. Slides were postﬁxed with 2%
osmium, 0.1 mol/l PO4, dehydrated, and embedded in Epon-812. Image
acquisition was performed with an electron microscope Phillips CM-10
(3,900 magniﬁcation). Double-immunogold labeling was performed as pre-
viously described (26) on human pancreatic sections. Stainings for insulin (5
nm gold) and nephrin (10 nm gold) were obtained with a rabbit polyclonal
anti-insulin antibody (Dako, Glostrup, Denmark) and the mouse monoclonal
anti-nephrin antibody 50A9.
Metabolic studies. In vitro and in vivo analysis of insulin production at
baseline and after glucose stimulation were performed as previously de-
scribed (27). Brieﬂy, control, nephrin siRNA treated, and nephrin-transfected
MIN6 cells were used for the in vitro analysis of the glucose stimulation index
(expressed as the ratio of insulin secreted at 20 mmol/l glucose to 2 mmol/l
glucose) after a 30-min stimulation with 20 mmol/l glucose in static incubation
experiments. Insulin content (cell lysates plus supernatants) and insulin
secretion (cell supernatants) were studied by enzyme-linked immunosorbent
assay (ELISA) (Mercodia, SW) and normalized per DNA content (Quanti-iT
PicoGreen dsDNA assay kit, Invitrogen). For perifusion studies in human
islets, 200,000 dissociated cells were loaded on microcolumns connected to an
inﬂow and an outﬂow port of a customized perifusion system (Biorep, Miami,
FL). Cells were perifused with media of deﬁned composition (3 mmol/l
glucose, 11 mmol/l glucose, and 25 mmol/l KCl), and samples were collected
every 2 min for insulin and DNA determination. For in vivo experiments,
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FIG. 2. Nephrin is expressed in human islets and -cells. A: Immunostaining for nephrin on normal human pancreas revealed a predominant
localization of nephrin to both small and large islets. B: Immunoﬂuorescence colocalization studies revealed a predominant localization of
nephrin (red) to insulin-producing cells (green, ﬁrst row) but not to glucagon, somatostatin, and CD31-positive cells (green, subsequent rows).
An irrelevant IgG2b was used as control and is shown in the last row. C: Western blotting analysis for nephrin. 1: COS7 (negative control), 2:
human podocytes, 3: fetal human pancreas, 4–6: human islets from three different donors, 7: human kidney, 8: MIN6 cells. D: Standard RT-PCR
for nephrin and actin. Samples 1–6 are of human origin, whereas 7–10 are of mouse origin. 1: kidney, 2: fetal pancreas, 3 and 5: whole pancreas
from two different donors, 4 and 6: islets from same donors, 7: kidney, 8: islets, 9: fetal pancreas, and 10: MIN6 cells. (A high-quality color digital
representation of this ﬁgure is available in the online issue.)
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192 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgpseudoislets were transplanted under the kidney capsule of diabetic immu-
nodeﬁcient athymic nu/nu (nude) mice (Harlan Labs) under protocols ap-
proved by the University of Miami Institutional Animal Care and Use
Committee (27). Sampling for glycemia was consistently performed in
the morning during the ﬁrst hour of light exposure. Intraperitoneal glucose
tolerance test (IPGTT) after 5-h fasting and after administration of a glucose
bolus (2 g/kg) was performed to assess the role of nephrin expression on
insulin secretion in vivo. Fasting serum before IPGTT was tested for the
presence of insulin by ultrasensitive insulin ELISA (Mercodia, SW).
Data analysis. Results represent the mean and SD of four to eight indepen-
dent experiments. When one-way ANOVA showed statistical signiﬁcance,
results were compared using t test after Tukey’s correction for multiple
comparisons (Graph Pad Prism software). Statistical signiﬁcance was set at
P  0.05.
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FIG. 3. Nephrin affects insulin content and glucose responsiveness in MIN6 cells. Nephrin overexpression resulted in increased total insulin
content (A) and glucose response in static incubation experiments (B, graphic representation with mean and SD of eight independent
experiments). The effect of nephrin siRNA on total insulin content (C) and glucose response in static incubation experiments (D) are also shown.
Representative blots showing nephrin protein level in transfected and siRNA-treated cells are shown (A and C). Nephrin overexpression resulted
in increased number of secretory vesicles (as evaluated by vesicles count in 20 separate electromicrographs) when compared with empty
vector–transfected cells (control) (E). F: Graphic representation of nonfasting glycemia evaluated daily in diabetic nude mice recipients of
nephrin-overexpressing pseudoislets (n  6) or control pseudoislets (n  5). G: IPGTT proﬁles of recipients of nephrin-overexpressing or control
pseudoislets performed 1 week after transplantation. H: Growth curves of monolayer of untransfected cells (control) when compared with empty
vector or nephrin-transfected cells. *P < 0.05, **P < 0.01.
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Nephrin expression is decreased in islets from pa-
tients with type 2 diabetes and is regulated by glu-
cose. We have studied nephrin mRNA expression in
human islets isolated from ﬁve patients with type 2 diabe-
tes and seven nondiabetic patients matched for age, sex,
and cold ischemia time (Fig. 1A). None of the diabetic
patients had reached insulin dependence. BMI was signif-
icantly higher in diabetic than in nondiabetic donors (P 
0.05), and nephrin expression was inversely related to BMI
(Fig. 1B). -Cell content was not signiﬁcantly different
(42 	 11% in diabetic vs. 49 	 14% in nondiabetic patients).
Confocal assessment of nephrin expression in human
islets from the same patients was consistent with the
downregulation of nephrin expression observed by PCR
(Fig. 1C). To understand if glucose had a role in the
regulation of nephrin expression observed in diabetes, we
studied nephrin expression after acute and chronic expo-
sure to glucose. We found that an acute exposure of islet
cells (both human islets and MIN-6 cells) to 20 mmol/l
glucose causes upregulation of nephrin expression (Fig.
1D and E), whereas the opposite effect was observed with
chronic exposure of MIN-6 cells to 20 mmol/l glucose (Fig.
1E). Nephrin expression was absent in human islets after
14 days in culture (data not shown).
Nephrin expression in islets is predominantly in
-cells. Nephrin immunostaining in normal human pan-
creas was present in islet cells regardless of islet size
(Fig. 2A). Immunoﬂuorescence colocalization studies
with nephrin, insulin, glucagon, somatostatin, and CD31
showed nephrin expression primarily in -cells (Fig.
2B). Nephrin expression in adult and fetal human pan-
creas, human islets, and murine insulinoma cells was
conﬁrmed by Western blot (Fig. 2C) and standard
RT-PCR (Fig. 2D). A 938-bp product of PCR ampliﬁca-
tion was sequenced to conﬁrm speciﬁc nephrin ampliﬁ-
cation. Both transcript splice variants described for
podocytes (24) were detected in pancreatic islets.
Nephrin affects GSIR in MIN6 cells. Nephrin overex-
pression was associated with signiﬁcantly higher insulin
content (Fig. 3A) and improved GSIR in static incubation
experiments when compared with control cells (Fig. 3B).
To further characterize the role of nephrin in -cell
function, insulinoma cells were treated with a selected
pool of four nephrin siRNAs with 85% efﬁciency. The
depletion of nephrin expression was paralleled by a de-
crease in insulin content (Fig. 3C) and in GSIR in vitro
(Fig. 3D). Nephrin expression was also compared between
the glucose responsive and the glucose unresponsive B1
and C3 MIN6 subclones. MIN6 B1 cells had threefold
higher nephrin expression than MIN6 C3 cells (3.1 	 0.5
vs. one relative quantiﬁcation in B1 vs. C3 respectively,
P  0.023). However, nephrin transfection of C3 cells was
not sufﬁcient to make them glucose responsive. Monolay-
ers of nephrin-transfected and empty vector–transfected
(control) cells were analyzed by electron microscopy for
vesicle quantiﬁcation. Nephrin-transfected cells had a sig-
niﬁcantly higher content of secretory granules and clusters
of secretory vesicles than control cells (Fig. 3E). The effect
of nephrin overexpression on insulin production and glu-
cose responsiveness was conﬁrmed in vivo upon trans-
plantation of nephrin and control pseudoislets in
immunodeﬁcient diabetic mice. Mice receiving nephrin-
positive pseudoislets had signiﬁcantly lower glycemia
starting at day 5 after transplantation (Fig. 3F), and
glucose tolerance tests performed at day 7 after transplan-
tation showed a faster reversal to normoglycemia in mice
that had received nephrin-positive pseudoislets when com-
pared with mice with pseudoislets transfected with the
empty vector control (Fig. 3G). All animals reverted to a
glycemia of 100 mg/dl after 80 min of glucose adminis-
tration. Serum insulin was detectable in nephrin-trans-
planted mice only (data not shown). All mice reverted to
hyperglycemia after nephrectomy of the graft-bearing kid-
ney, suggesting that the transplanted pseudoislets were
responsible for the correction of diabetes. No difference in
the growth rate of nephrin-transfected cells and cells
transfected with an empty vector or untransfected cells
was observed (Fig. 3H).
Nephrin affects GSIR in human islets. To overcome the
limitation of using insulinoma cells to study the role of
nephrin in insulin secretion, we applied nephrin siRNA
gene downregulation to dissociated human islet cells
(from four different donors). A mean silencing efﬁciency of
62% was achieved (Fig. 4A). Cell viability evaluated in
siRNA-treated dissociated cells by Trypan blue exclusion
was also conserved (data not shown). Nephrin siRNA
affected both the ﬁrst and the second phase of glucose
response in perifused islet cells when compared with
nontargeting siRNA (Fig. 4B). Response to KCl was con-
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FIG. 4. Nephrin affects glucose responsiveness in human islets. A:
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dependent insulin exocytosis is probably not under the
direct inﬂuence of nephrin.
Nephrin localizes to both plasma membrane and in-
sulin vesicles of pancreatic -cells. Confocal micros-
copy of -cells from human pancreatic sections revealed a
prevalent granular cytoplasmic localization with partial
insulin colocalization (Fig. 5A). Double-immunogold label-
ing for nephrin and insulin of normal human pancreas
revealed a prevalent localization of nephrin at the periph-
ery of insulin vesicles (Fig. 5B1). When analyzing vesicles
in the process of fusing to the plasma membrane, nephrin
remains predominantly localized to the fused membrane
(Fig. 5B2). Nephrin localization to the plasma membrane
independent of insulin vesicles could also be observed
(Fig. 5B3). Nephrin staining was also detectable in few
empty vesicles (5%). Immunoﬂuorescence analysis of
nephrin localization in cultured MIN6 cells revealed a
partial colocalization of nephrin with insulin and VAMP2
(Fig. 5C). Biotinylation experiments revealed a predomi-
nant cytosolic localization (unbound) and a limited plasma
membrane localization (bound, Fig. 5D). Proper separa-
tion was conﬁrmed by reblotting the membranes for Na/K
ATPase (Fig. 5D).
Glucose affects nephrin endocytosis. Because nephrin
was localized in both plasma membrane and insulin vesi-
cles, and nephrin endocytosis was reported in podocytes
(28), we investigated if the glucose concentration affected
the subcellular localization of nephrin. For this purpose,
GFP-nephrin–transfected cells were used for confocal
imaging (Fig. 6A). When cells were co-stained with the live
membrane dye FM4–64 used to visualize vesicles, nephrin
localization was primarily at the plasma membrane in cells
cultured at 2 mmol/l glucose and partially underwent
endocytosis after stimulation with 20 mmol/l glucose (Fig.
6B). Subcellular fractionation experiments in untrans-
fected MIN6 cells were used to conﬁrm ﬁndings by im-
munoﬂorescence. Nephrin was clearly detectable in
E-cadherin–positive plasma membrane fractions from
MIN6 cells cultured in 0.5 mmol/l glucose, but the nephrin/
E-cadherin relative intensity was markedly decreased in 25
mmol/l glucose (Fig. 6C). On the contrary, when analyzing
vesicle fractions (VAMP2-positive), nephrin- and insulin-
positive vesicle fractions were present in both 0.5 and 25
mmol/l glucose.
Nephrin augmentation of insulin secretion is par-
tially dependent on actin cytoskeleton remodeling.
Actin depolymerizing agents have been shown to affect
insulin secretion by pancreatic -cells (15,29), while more
complex may be the role of actin-stabilizing/nucleating
drugs such as jasplakinolide, which has been clearly
shown to increase glucose responsiveness in MIN6 cells
when used at high concentrations (30). Nephrin increases
insulin secretion (Fig. 3), and nephrin modulates actin
Insulin A
C
B
D
Nephrin
DAPI
Insulin
Nephrin
VAMP2
63x5x
63x5x 63x5x
63x5x 63x5x
40x
12
biotinylated
Nephrin
180 kD
Na/K
ATPase
non biotinylated
W
h
o
l
e
W
h
o
l
e
B
o
u
n
d
B
o
u
n
d
U
n
b
o
u
n
d
U
n
b
o
u
n
d
3
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nephrin trafﬁcking from the plasma membrane to the
cytoplasm can be prevented by actin stabilization with
low-dose jasplakinolide and if the positive nephrin effect
on insulin secretion could be abolished. Both glucose and
cytochalasin D induced a redistribution of nephrin from
the plasma membrane to the cytoplasm (Fig. 7A and C),
and jasplakinolide completely prevented this effect (Fig.
7B), similar to what we observed with 200 nmol/l
phalloidin treatment (data not shown). The augmenta-
tion of GSIR in nephrin-transfected cells was also
prevented by jasplakinolide (Fig. 7D), suggesting that a
nephrin-mediated increase in insulin secretion is partially
dependent on the polymerization status of actin. The actin
remodeling function of cytochalasin D, jasplakinolide, and
phalloidin was studied by Western blotting for G- and
F-actin subcellular fractions. While untreated MIN6 cells
are characterized by a content of F-actin of 
40% of total
actin, cytochalasin D treatment resulted in a decrease
F-actin content to 10%, and jasplakinolide and phalloidin
both increased F-actin content to 60 and 65%, respectively
(Fig. 7E).
DISCUSSION
The present study unveiled that nephrin affects the func-
tion of pancreatic -cells and promotes insulin secretion in
response to glucose. This function of nephrin is indepen-
dent from its well-known and described role in kidney
podocytes, where it regulates structure and function of the
glomerular slit diaphragm (10,31,32). The regulation of
insulin secretion by nephrin is also different from a
recently described function in skeletal muscles, where
nephrin is responsible for secondary fusion of myoblasts
into nascent myotubules (33). Despite such apparent dis-
crepant functions of nephrin in different organs, a com-
mon mechanisms of action remains the ability of nephrin
to modulate actin cytoskeleton remodeling (9,13), a phe-
nomenon that is equally important for the function of
pancreatic -cells, podocytes, and skeletal muscles. The
existing controversial data on nephrin expression in pan-
creatic islets (7,34,35) has prompted us to conﬁrm nephrin
expression in human pancreas. Here we clearly showed
that nephrin is expressed in human pancreas predomi-
nantly in pancreatic -cells (Fig. 2). Of note, in -cells,
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containing vesicles (Fig. 5B), suggesting a role for nephrin
as a modulator of vesicle trafﬁcking during insulin secre-
tion. This vesicle associated intracellular localization was
unexpected, because in podocytes, nephrin has been de-
scribed as a plasma membrane protein involved in cell-cell
adhesion via homophilic (36,37) and heterophilic interac-
tions (38–40). As it stands, there are no reports of any
endocrine dysfunctions in patients with gene mutations in
the nephrin NPHS1 gene, and glucose tolerance tests
performed in this subgroup of patients are normal (35).
This, however, does not exclude that nephrin may be
relevant to -cell function, since truncated nephrin iso-
forms may still be functional in the pancreas. Interestingly,
while nephrin in podocytes interacts with other proteins
such as podocin and Neph1 to facilitate nephrin-mediated
signaling, those proteins have not been detected in the
pancreas (41). Together, these observations raise the
intriguing possibility that nephrin serves a different func-
tion in the pancreas than in the kidney.
To investigate nephrin function, we manipulated neph-
rin expression in insulinoma MIN6 cells and dissociated
human islets and established a role for nephrin in both
GSIR and in total insulin production (Figs. 3 and 4).
Although the increased total insulin content could result
from a direct effect of nephrin on insulin transcription, it
could also be the consequence of a well-characterized
feedback mechanism to increase insulin production and
vesicle formation upon insulin secretion (42), as suggested
by the electron microscopy quantiﬁcation of the number of
secretory vesicles in nephrin-transfected cells (Fig. 3E). It
is also possible that nephrin is involved in the machinery
enabling glucose entry and metabolism, which may ex-
plain why nephrin downregulation did not affect signiﬁ-
cantly KCl response. Decreased nephrin expression in the
MIN6-C3 subline compared with the MIN6-B1 subline was
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this context, it will be interesting to test whether this is
due to the decreased MIN6-C3 expression of gelsolin,
another actin regulator that may play an important role in
glucose-stimulated actin remodeling (29).
The localization of nephrin on both the plasma mem-
brane and insulin vesicles, together with the known ability
of nephrin to modulate actin cytoskeleton remodeling and
to undergo endocytosis in podocytes (28), has prompted
us to explore if nephrin endocytosis would occur as a
consequence of glucose stimulation and would affect
insulin release. Our ﬁnding that nephrin undergoes endo-
cytosis upon glucose stimulation is in keeping with the
hypothesis that nephrin relocation from the plasma mem-
brane to the cytoplasm facilitates insulin release, probably
through disruption of the dense web of cortical actin that
prevents insulin vesicle fusion to the plasma membrane
(43,44). In fact, actin stabilization with phalloidin and
jasplakinolide prevented nephrin endocytosis and abol-
ished nephrin effect on increased insulin secretion. We
have used a dose of jasplakinolide that speciﬁcally leads to
actin stabilization, as the effects of jasplakinolide on the
kinetics of actin polymerization are highly time and dose
dependent (45). The opposite effect on insulin secretion
and glucose responsiveness were reported in very elegant
studies in whole islets and insulinoma cells where a
10-fold higher concentration of jasplakinolide was used
(30), suggesting a multifaceted role of the actin cytoskel-
eton in the regulation of GSIR. Further studies will be
needed to deﬁne the precise mechanism whereby nephrin
augments insulin secretion.
Another interesting ﬁnding of the present study was the
observation that nephrin expression is decreased in islets
from diabetic patients when compared with age-matched
nondiabetic control subjects, similar to what has been
reported in the kidney (5). BMI and nephrin mRNA expres-
sion was inversely related in pancreatic islets, supporting
a critical role of nephrin in GSIR. Consistent with these
ideas, prolonged exposure to high glucose led to a down-
regulation of nephrin expression in MIN6 cells, while
acute exposure to high glucose increased nephrin mRNA
expression. Although the relevance of an in vitro model of
acute and prolonged glucose exposure in insulinoma cells
remains to be established, the opposite effect of acute and
chronic glucose exposure on nephrin gene expression is
consistent to what has been described in kidney cells (46),
where chronic glucose exposure has been widely accepted
as a model of glucotoxicity (18). One possible interpreta-
tion of our results is that nephrin allows a more dynamic
vesicle mobilization and increased insulin secretion,
which may be impaired in diabetes because of the down-
regulation of nephrin in pancreatic -cells.
In conclusion, our results identiﬁed nephrin as an im-
portant regulator of glucose-stimulated insulin secretion in
pancreatic -cells. Our data suggest that nephrin is an
active component of the vesicle machinery that guarantees
the interaction of insulin vesicles with the actin cytoskel-
eton and thereby their mobilization toward the plasma
membrane. Thus, interventions that lead to increased
nephrin expression and/or function may delay the need for
insulin therapy in type 2 diabetes. Whether an active role
of nephrin in vesicle exocytosis in podocytes contributes
to the integrity of the slit diaphragm remains to be
explored.
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